墨索里尼Invernizzi % 0期刊文章%,%巴内特,约瑟夫%拉瓦尔大声回答,Bhavin % Nair, Arjun %佳日,Poonam %金斯敦,肖恩%蔡,菲利克斯%吴,哲%井,Renzoni Athol美国的%,伊丽莎白·r·%尼克尔森,安德鲁·g . %大米,亚历山德拉%劳埃德,克莱尔m % Byrne,亚当•j . %马赫托比m % Devaraj, Anand Molyneaux %,菲利普·l . % T细菌负担较低的航空公司预计在特发性肺纤维化疾病进展和独立于放射性疾病程度2020% % D J R 10.1183/13993003.01519 -2019%欧洲呼吸杂志% P 1901519 % X增加细菌负担降低航空公司的特发性肺纤维化患者带来疾病进展的风险增加和死亡率。然而，尚不清楚这种增加的细菌负担是直接影响纤维化的进展，还是仅仅反映了潜在疾病的严重程度或严重程度。我们前瞻性地招募了193名接受支气管镜检查并接受多学科诊断的特发性肺纤维化患者。采用16S rRNA基因qPCR定量分析支气管肺泡灌洗液中细菌总负担。成像由两名阅读者独立评估，并对放射学变化的程度、严重程度和地形图进行定量评分，并评估这些特征与细菌负担的关系。细菌负担增加与疾病进展显著相关(危险比2.1;95%置信区间1.287-3.474;p = 0.0028)。多变量逐步回归显示细菌负担与放射学特征或疾病程度之间没有关系。当特别考虑明确的或可能的常见间质性肺炎患者时，两组间的细菌负担没有差异。尽管胸膜实质纤维弹性变性与临床感染之间存在假定的联系，但胸膜实质纤维弹性变性的存在或程度与细菌负担之间均无关系。我们证明，下气道的细菌负担并不仅仅是继发性的，与特发性肺纤维化中肺实质的基础结构破坏程度相关。 The independent nature of this association supports a relationship with the underlying pathogenic mechanisms and highlights the urgent need for functional studies.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Rachele Invernizzi has nothing to disclose.Conflict of interest: Dr Joseph Barnett has nothing to disclose.Conflict of interest: Bhavin Rawal has nothing to disclose.Conflict of interest: Poonam Ghai has nothing to disclose.Conflict of interest: Dr Shaun Kingston has nothing to disclose.Conflict of interest: Dr Felix Chua has nothing to disclose.Conflict of interest: Zhe Wu has nothing to disclose.Conflict of interest: Prof. Athol Wells reports speakers and consultancy fees from Intermune Roche, Boehringer ingelheim and Bayer.Conflict of interest: Dr Elizabeth Renzoni has received speakers fees from BI, Roche and Mundipharma.Conflict of interest: Prof. Andrew Nicholson reports personal fees from MEDICAL QUANTITATIVE IMAGE ANALYSIS, personal fees from BOEHRINGER INGELHEIM, personal fees from ROCHE, personal fees from SANOFI, outside the submitted work.Conflict of interest: Dr Alexandra Rice reports Shareholder in Pfizer.Conflict of interest: Prof. Clare Lloyd has nothing to disclose.Conflict of interest: Dr Adam Byrne has nothing to disclose.Conflict of interest: Prof. Toby Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speakers fees from Apellis, Astra Zeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, GlaxoSmithKline R&D, Indalo, Novartis, Pliant, ProMetic, Respivnat, Roche, Samumed and UCB.Conflict of interest: Dr Anand Devaraj reports personal fees from GSK, personal fees from Roche, personal fees from boehringer ingelheim, outside the submitted work.Conflict of interest: Dr Philip Molyneaux has, via his institution, received industry-academic funding from Roche, Boehringer Ingelheim and Galapagos and has received speakers fees from Roche.Conflict of interest: Dr Arjun Nair has nothing to disclose. %U //www.qdcxjkg.com/content/erj/early/2020/01/03/13993003.01519-2019.full.pdf